Related Experiment Videos
Liver disease associated with alpha1-antitrypsin deficiency in childhood
Insights
Children with alpha1-antitrypsin deficiency (AATD) ZZ type may not have a poor liver disease prognosis. Early SGOT elevation and other health issues indicate a worse outlook, but many patients show mild liver disease.
Area of Science:
- Pediatric Hepatology
- Genetic Liver Diseases
- Pulmonology
Background:
- Alpha1-antitrypsin deficiency (AATD) is a genetic disorder that can lead to liver and lung disease.
- Protease inhibitor (PI) type ZZ is the most common severe form of AATD.
- Neonatal hepatitis syndrome is a frequent presentation of liver disease in infants.
Purpose of the Study:
- To evaluate the long-term prognosis of liver disease in children with AATD, PI type ZZ.
- To identify factors associated with a poor prognosis in this patient group.
- To assess the utility of liver biopsy in predicting outcomes.
Main Methods:
- Retrospective analysis of 18 pediatric patients with AATD, PI type ZZ.
- Clinical, biochemical, and histological data review.
- Correlation of early clinical signs and laboratory values with long-term outcomes.
Main Results:
- Most patients (11/18) showed mild liver disease despite initial presentation with neonatal hepatitis or hepatomegaly.
- Four patients died from cirrhosis-related complications; three have severe liver disease.
- Persistent elevated SGOT in the third year of life, renal, or pulmonary issues were linked to poor prognosis.
- Early liver biopsy was not prognostic but useful for assessing severity and alpha1AT storage.
- AATD was found in 29% of neonatal hepatitis cases; one asymptomatic sibling had undiagnosed liver disease.
Conclusions:
- Liver disease in children with AATD ZZ type does not always have a poor prognosis.
- Early identification of prognostic indicators like elevated SGOT and comorbidities is crucial.
- Screening of at-risk siblings is important for early diagnosis and management.
Abstract:
Liver disease in children with alpha1-antitrypsin deficiency and protease inhibitor type ZZ does not necessarily carry a bad prognosis. Fourteen of our 18 patients presented with the neonatal hepatitis syndrome and four had hepatomegaly without jaundice. Although four patients have died of cirrhosis and its complications, and three have severe liver disease, most of the 11 others, of whom four are over 13 years of age, have relatively little clinical, biochemical, or histologic evidence of liver disease. Persistent elevation of SGOT during the third year of life and renal or pulmonary problems were associated with a poor prognosis. Liver biopsy early in the course of the disease was not helpful prognostically but was useful in assessment of the severity of liver disease and demonstration of alpha1AT storage, alpha1AT deficiency was found in 29% of our patients who presented with the neonatal hepatitis syndrome. One of seven apparently healthy Pi type ZZ sibs of our patients had significant liver disease which had not been suspected previously.